DHODH and COVID-19: How FSP1pathway relates specifically to COVID-19 pathophysiology has not been investigated yet, conversely a very recent review reported the outcomes of two preliminary in-vitro studies where DHODH inhibitors halted SARS-CoV-2 replication.